Table 3.
Univariate Model for Predicting Treatment Failure
| Variable | *N | HR (95% CI) | P value |
|---|---|---|---|
|
| |||
| PET metastasis (any site) | 106 | 3.83 (2.30, 6.38) | <.0001 |
|
| |||
| Clinical Gleason Score | 106 | 0.1092 | |
| 6 vs. 7 | 0.46 (0.11, 1.97) | ||
| (8, 9, 10) vs. 7 | 1.51 (0.89, 2.55) | ||
|
| |||
| Percent cores positive | 101 | 1.01 (1.00, 1.02) | 0.0140 |
|
| |||
| PSA (ng/mL) | 106 | 1.01 (1.00, 1.01) | 0.0563 |
|
| |||
| Clinical Stage (cT2 vs cT1c) | 103 | 1.39 (0.814, 2.36) | 0.2294 |
|
| |||
| SUV (primary prostate cancer) | 106 | 1.11 (0.97, 1.26) | 0.1285 |
|
| |||
| Pathology Gleason Score | 102 | <.0001 | |
| 6 vs. 7 | 0.26 (0.04, 1.96) | ||
| (8, 9, 10) vs. 7 | 2.82(1.67, 4.76) | ||
|
| |||
| Pathology Stage | 101 | <.0001 | |
| 3a vs. 2 | 2.93 (1.39, 6.20) | ||
| 3b vs. 2 | 9.15 (4.47, 18.70) | ||
|
| |||
| Surgical Margins | 102 | 2.56 (1.50, 4.37) | 0.0006 |
*
Number of patients for which variable was available.